BioSyent Inc. Acquires 5,100 Shares of BioSyent Inc. (CVE:RX) Stock

BioSyent Inc. (CVE:RX) insider BioSyent Inc. acquired 5,100 shares of the stock in a transaction dated Monday, April 29th. The stock was acquired at an average price of C$8.55 per share, with a total value of C$43,627.95.

BioSyent Trading Up 0.9 %

RX opened at C$8.59 on Friday. BioSyent Inc. has a one year low of C$7.03 and a one year high of C$9.26. The company has a debt-to-equity ratio of 3.51, a current ratio of 6.48 and a quick ratio of 6.91. The business has a 50 day simple moving average of C$8.60 and a two-hundred day simple moving average of C$8.54. The firm has a market capitalization of C$99.73 million, a price-to-earnings ratio of 16.21 and a beta of 0.93.

BioSyent (CVE:RX) last announced its quarterly earnings results on Wednesday, March 13th. The company reported C$0.12 EPS for the quarter, missing analysts’ consensus estimates of C$0.17 by C($0.05). The business had revenue of C$8.27 million during the quarter, compared to analysts’ expectations of C$8.80 million. BioSyent had a return on equity of 18.97% and a net margin of 20.45%. Analysts predict that BioSyent Inc. will post 0.4695983 EPS for the current year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.